The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLVI.b

Pulmonary arterial hypertension

Publications

Grynblat J, Khouri C, Hlavaty A, Jaïs X, Savale L, Chaumais MC, Kularatne M, Jevnikar M, Boucly A, Antigny F, Perros F, Simonneau G, Sitbon O, Humbert M, Montani D,

Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.

The European respiratory journal 2024 Jun;63; — 2024 Jun

Yang JZ, Buckstaff T, Narezkina A, Fernandes TM

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma.

Pulmonary circulation 2021 Oct-Dec;11;20458940211049300 — 2021 Oct-Dec — 20458940211049300

Chari A, Hajje D

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.

BMC cancer 2014 Dec 04;14;915 — 2014 Dec 04 — 915